Cleland, John G.F.
John G. F. Cleland
Cleland, John
Cleland, John G. F., 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 1691886 (Personal)
Permalink: http://viaf.org/viaf/1691886
Preferred Forms
-
200 _ 1 ‡a Cleland ‡b John G.F.
-
100 1 _
‡a
Cleland, John
-
100 1 _ ‡a Cleland, John G. F
-
100 1 _
‡a
Cleland, John G. F
-
100 1 _
‡a
Cleland, John G. F
-
100 1 _
‡a
Cleland, John G. F.
-
100 1 _ ‡a Cleland, John G. F.
-
100 1 _ ‡a Cleland, John G. F.
-
100 1 0
‡a
Cleland, John G. F.
-
100 1 _
‡a
Cleland, John G. F.
-
100 1 _
‡a
Cleland, John G. F.,
‡d
19..-....
-
100 1 _ ‡a Cleland, John G.F.
-
100 0 _
‡a
John G. F. Cleland
4xx's: Alternate Name Forms (11)
5xx's: Related Names (2)
Works
| Title | Sources |
|---|---|
| Angiotensin converting enzyme inhibition : changing the course of cardiovascular disease : Proceedings of an |
|
| Angiotensin II antagonism : a new advance in the treatment of hypertension : satellite symposium to the 6th European meeting on hypertension, 3 June 1993, Milan, Italy |
|
| Aspirin use is associated with increased risk for incident heart failure: a patient‐level pooled analysis |
|
| The Clinician's guide to ACE inhibition, 1993: |
|
| Controversies in the management of heart failure |
|
| A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure |
|
| effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial |
|
| From hypertension to heart failure |
|
| Health-economic issues in cardiovascular disease : proceedings of a symposium held in Munich, 8 September 1994 |
|
| Is the Controlled Rosuvastatin Multinational Study in Heart Failure |
|
| Is the Way to a Man’s Heart Through His Stomach? |
|
| Kontrowersje w leczeniu niewydolności serca |
|
| Left ventricular morphology, global and longitudinal function in normal older individuals: A cardiac magnetic resonance study |
|
| Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. |
|
| Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE |
|
| Lipid-Modifying Treatments for Heart Failure |
|
| Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. |
|
| Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. |
|
| Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study |
|
| Med. dir., 1993: |
|
| Metabolic gas kinetics depend upon the level of exercise performed |
|
| Metabolic remodeling in the aging heart |
|
| A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent |
|
| Methodological Shortcomings of Wrist-Worn Heart Rate Monitors Validations |
|
| MicroRNAs relate to early worsening of renal function in patients with acute heart failure |
|
| N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population |
|
| New generation 3-dimensional echocardiography for left ventricular volumetric and functional measurements: comparison with cardiac magnetic resonance. |
|
| Obituary to Philip Poole-Wilson 1943-2009. |
|
| Od nadciśnienia tętniczego do niewydolności krążenia / J. G. F. Cleland, J. McMurry. - Gdańsk, 1998. |
|
| The perindopril in elderly people with chronic heart failure (PEP-CHF) study |
|
| Pharmacokinetic and Pharmacodynamic Characteristics of β-Blockers: When Differences May Matter |
|
| A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design |
|
| Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group |
|
| Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome |
|
| Poor Relationship Between Exercise Capacity and Spirometric Measurements in Patients With More Symptomatic Heart Failure |
|
| Practical applications of intravenous diuretic therapy in decompensated heart failure |
|
| Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System |
|
| Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction. |
|
| The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure |
|
| Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey |
|
| Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. |
|
| Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure |
|
| Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance study |
|
| Prevention of and medical therapy for atrial arrhythmias in heart failure. |
|
| Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. |
|
| Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure |
|
| Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. |
|
| Prognostic value of the VE/VCO2 slope calculated from different time intervals in patients with suspected heart failure |
|
| Progress in ACE inhibition |
|
| Pulmonary artery pressure measurement during exercise testing in patients with suspected pulmonary hypertension |
|
| QRS morphology as a predictor of the response to cardiac resynchronisation therapy: fact or fashion? |
|
| The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy |
|
| The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization |
|
| Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? |
|
| Understanding heart failure |
|
| Unmasking the truth. |
|
| Update of REACH-1 and MERIT-HF clinical trials in heart failure |
|
| Use of carotid intima-media thickness regression to guide therapy and management of cardiac risks. |
|
| The utility of novel non-invasive technologies for remote hemodynamic monitoring in chronic heart failure. |
|
| Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease. |
|
| The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics |
|
| The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure |
|
| When Is it Appropriate to Withdraw Cardiac Resynchronization Therapy? Guesses and Evidence ∗ |
|
| Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study |
|
| Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. |
|
| Wytyczne European Society of Cardiology dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku |
|
| Xanthine Oxidase Inhibition for the Treatment of Cardiovascular Disease: A Systematic Review and Meta-Analysis |
|
| The year in cardiology: heart failure |
|
| Yoku wakaru shinfuzen : Oisha ni yuku mae ni mazu yomu hon |
|
| প্রত্যুত্তর |
|
| ਡੀਫਿਬਰਿਲਟਰ—ਕਾਰਡੀਓਮਾਇਓਪੈਥੀ ਲਈ ਹੈਰਾਨ ਕਰਨ ਵਾਲੀ ਥੈਰੇਪੀ? |
|
| 심장기능부전 |
|
| よくわかる心不全 : お医者に行く前にまず読む本 |
|
